Alan Louis Urban

CIK: 0001534376

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GTBP

GT Biopharma, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

GTBP
GT Biopharma, Inc.
Sep 4, 2025
Award(A)
Option to purchase Common Stock
Direct
50K shares-
GTBP
GT Biopharma, Inc.
Sep 4, 2025
Award(A)
Option to purchase Common Stock
Direct
50K shares-
GTBP
GT Biopharma, Inc.
Oct 17, 2024
Award(A)
Option to purchase Common Stock
Direct
23.3K shares-

		Type	Shares	Price		Ownership
Sep 4, 2025	GTBP GT Biopharma, Inc.	Award(A) Option to purchase Common Stock	50,000	-	-	Direct
Sep 4, 2025	GTBP GT Biopharma, Inc.	Award(A) Option to purchase Common Stock	50,000	-	-	Direct
Oct 17, 2024	GTBP GT Biopharma, Inc.	Award(A) Option to purchase Common Stock	23,335	-	-	Direct

1-3 of 3 transactions

About URBAN ALAN LOUIS

URBAN ALAN LOUIS (SEC CIK 0001534376) files insider reports with the SEC as Chief Financial Officer of GT Biopharma, Inc. (GTBP).

Signal8 holds 2 ownership filings by URBAN ALAN LOUIS, all Form 4s, filed between Oct 21, 2024 and Sep 8, 2025. Those filings report 3 transactions, from Oct 17, 2024 to Sep 4, 2025. Signal8's Form 4 history starts in Sep 2024.

Recent filings by URBAN ALAN LOUIS

Sep 4, 2025: Grants or awards of GTBP derivative securities (2 lines, Form 4, code A).
Oct 17, 2024: Grant or award of GTBP derivative securities (Form 4, code A).

Other insiders filing for GT Biopharma, Inc. (GTBP)

Mun-Gavin David C., Director
Breen Michael Martin, CEO and Director
CASAMENTO CHARLES J, Director
Kramer Hilary, Director
Ritter Andrew J, Director

How to read Form 4 transaction codes